HPTN 027

A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi October 01, 2006
ALVAC-HIV vCP1521 Canarypox Env B,E
ALVAC-HIV vCP1521 Viral Vector - Pox
Uganda 50